Assaf Hilely, ESCRS 2020 – Non-neovascular Age-related Macular Degeneration with Subretinal Fluid
We caught up with Editorial Board member Dr Assaf Hilely (Tel Aviv Medical Center, Tel Aviv, Israel), who talked us through his recent study of non-neovascular age-related macular degeneration with subretinal fluid.
- What prognostic factors are currently used to guide treatment when initiating anti-vascular endothelial growth factor treatment for patients with age-related macular degeneration (AMD) with and without neovascularisation? (00:07)
- What was the rationale for investigating patterns of subretinal fluid in eyes with AMD without neovascularisation? (01:22)
- Could you tell us a little about the aims and design of your recent study? (02:12)
- What were the findings of the study? (03:20)
- What will be the impact of these findings on clinical practice and what future studies are planned? (04:53)
Speaker Disclosure: Dr Assaf Hilely has no financial or non-financial relationships or activities to declare in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ESCRS 2020.
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!